Literature DB >> 24723452

Immunotherapy for hepatoma using a dual-function vector with both immunostimulatory and pim-3-silencing effects.

Qie Guo1, Peixiang Lan2, Xin Yu2, Qiuju Han2, Jian Zhang2, Zhigang Tian1, Cai Zhang3.   

Abstract

Tumorigenesis is an immortalization process in which the growth of normal cells is uncontrolled and programmed cell death is suppressed. Molecular biologic and immunologic studies have revealed that the aberrant expression of some proto-oncogenes boosts proliferation and inhibits apoptosis, which is vital for tumor development. The hypofunction of the host immune system also drives the development and metastasis of malignant tumors. Pim-3, a member of the Pim family, is aberrantly expressed in several cancers. Data suggest that Pim-3 inhibits apoptosis by phosphorylating the proapoptotic BH3-only protein Bad. Here, we constructed a dual-function small hairpin RNA (shRNA) vector containing an shRNA targeting Pim-3 and a TLR7-stimulating ssRNA. Stimulation with this bi-functional vector in vitro promoted significant apoptosis of Hepa1-6 cells by regulating the expression of apoptosis-related proteins and induced secretion of type I IFNs. Most importantly, this bi-functional vector more effectively inhibited subcutaneous Hepa1-6 cell growth than did single shRNA and ssRNA treatment in vivo. Natural killer (NK), CD4(+) T, and CD8(+) T cells and macrophages were required for effective tumor suppression, and CD4(+) T cells were shown to play a helper role in the activation of NK cells, possibly by regulating the secretion of Th1 or Th2 cytokines. This ssRNA-shRNA bi-functional vector may represent a promising approach for tumor therapy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24723452     DOI: 10.1158/1535-7163.MCT-13-0722

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  15 in total

1.  Intestinal Lamina Propria CD4+ T Cells Promote Bactericidal Activity of Macrophages via Galectin-9 and Tim-3 Interaction during Salmonella enterica Serovar Typhimurium Infection.

Authors:  Xin Yu; Hongru Zhang; Linyan Yu; Meifang Liu; Zengyan Zuo; Qiuju Han; Jian Zhang; Zhigang Tian; Cai Zhang
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

Review 2.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy.

Authors:  Fanfei Meng; Jianping Wang; Yoon Yeo
Journal:  J Control Release       Date:  2022-03-26       Impact factor: 11.467

4.  Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation.

Authors:  Jing Liu; Xinyu Qu; Liwei Shao; Yuan Hu; Xin Yu; Peixiang Lan; Qie Guo; Qiuju Han; Jian Zhang; Cai Zhang
Journal:  Cancer Biol Ther       Date:  2018-01-25       Impact factor: 4.742

5.  Role of natural killer cells in liver transplantation treatment of liver cancer.

Authors:  Wenbin Ji; Jin Chen; Yuche Mi; Guiliang Wang; Xinjiang Xu; Weizheng Wang
Journal:  Exp Ther Med       Date:  2017-07-09       Impact factor: 2.447

Review 6.  Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.

Authors:  Cheng Sun; Hao-yu Sun; Wei-hua Xiao; Cai Zhang; Zhi-gang Tian
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

7.  Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells.

Authors:  Qie Guo; Zhong-Guo Sui; Wen Xu; Xiang-Hua Quan; Jia-Lin Sun; Xiao Li; Hong-Yan Ji; Fan-Bo Jing
Journal:  Oncotarget       Date:  2017-08-10

Review 8.  Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review.

Authors:  Faezeh Hosseinzadeh; Javad Verdi; Jafar Ai; Saieh Hajighasemlou; Iman Seyhoun; Frzad Parvizpour; Fatemeh Hosseinzadeh; Abolfazl Iranikhah; Sadegh Shirian
Journal:  Cancer Cell Int       Date:  2018-09-10       Impact factor: 5.722

9.  Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.

Authors:  S Kreuz; K B Holmes; R M Tooze; P F Lefevre
Journal:  Mol Cancer       Date:  2015-12-08       Impact factor: 27.401

10.  Immunotherapy of Dual-Function Vector with Both Immunostimulatory and B-Cell Lymphoma 2 (Bcl-2)-Silencing Effects on Gastric Carcinoma.

Authors:  Lanying Ma; Mei Han; Zumureti Keyoumu; Hua Wang; Saifuding Keyoumu
Journal:  Med Sci Monit       Date:  2017-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.